REG - AstraZeneca PLC - Board Committee Changes

AstraZenecaAnnouncement

26/06/2018 07:05

RNS Number : 5247S
AstraZeneca PLC
26 June 2018
 


26 June 2018 07:00 BST
 
BOARD COMMITTEE CHANGES
 
AstraZeneca PLC (the Company) today announced the following Board Committee changes.
 
Science Committee:
With effect from 1 July 2018, Nazneen Rahman will become permanent Chairman of the Science Committee.  Professor Rahman joined the Science Committee on her appointment as a Director on 1 June 2017 and has been interim Chairman of the Committee since November 2017.
 
Audit Committee:
With effect from 30 June 2018, Shriti Vadera will step down as a member of the Audit Committee.  As previously announced, Shriti Vadera has informed the Board that she will retire as a Director by 31 December 2018.  With effect from 1 November 2018, Deborah DiSanzo will become a member of the Audit Committee.
 
Remuneration Committee:
With effect from 1 July 2018, Sheri McCoy will become a member of the Remuneration Committee.
 
Nomination and Governance Committee:
With effect from 1 July 2018, Nazneen Rahman will become a member of the Nomination and Governance Committee.
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 



Media Relations












Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen


 
 


+44 203 749 5712




Josie Afolabi






+44 203 749 5631




Craig Marks


Finance; Fixed Income; M&A


+44 7881 615 764




Henry Wheeler


Oncology


+44 203 749 5797




Mitchell Chan


Oncology; Other


+1 240 477 3771




Christer Gruvris


Brilinta; Diabetes


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free






+1 866 381 7277

















Adrian Kemp

Company Secretary
AstraZeneca PLC
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAEAXKSADXPEFF